In November 2015, the U.S. Food and Drug Administration approved daratumumab for treatment of multiple myeloma in patients who had received at least three prior therapies. In May 2016 daratumumab was also conditionally approved by the European Medicines Agency for treatment of multiple myeloma.

In November 2016, the FDA approved daratumumab in combination with lenalidomide or bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy...Wikipedia

Manufacturer's Website: Darzalex                                                                                                                  Average retail cost: $512/vial